Why wasn’t a beta-blocker tested as first-line therapy?

Slides:

Advertisements

Similar presentations

How were step-up drugs selected and used in ALLHAT?

Advertisements

U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Review of Heart Failure Events in.

Newly diagnosed hypertensive patients with type 2 diabetes (n = 1544) Randomisation Avoid ACE inhibitors/ beta-blockers (n = 390) Tight BP control (n =

11/2/ Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.

1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.

CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.

Benefits of intensive multiple risk factor intervention.

Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.

Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.

WHEN SHOULD ONE INITIATE SUCCESSIVE ANTIHYPERTENSIVE DRUGS? Henry R. Black M.D. RUSH University Medical Center Chicago, IL June 15, 2005.

1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.

Did Type of Prior Antihypertensive Therapy Influence the Heart Failure Results in ALLHAT? Richard Grimm, Barry Davis, Linda Piller, Karen Margolis, Joshua.

Recent Developments in the Treatment of Hypertension The Value of Facts 1999.

Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.

1 Presenter Disclosure Information FINANCIAL DISCLOSURE: DSMB’s: Merck, Takeda Barry R. Davis, MD, PhD Clinical Outcomes in Participants with Dysmetabolic.

6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

DR. IDOWU AKOLADE EDM DIVISION LUTH

Hypertension Cost effectiveness Mark Caulfield For the British Hypertension Society The William Harvey Research Institute and Barts and The London NIHR.

Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,

Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal

1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.

1 Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial ALLHAT Davis.

Bezafibrate Infarction Prevention Trial (BIP) Results Presented at the European Society of Cardiology Meeting Vienna, Austria 1998.

10/11/ Fasting Glucose Levels & Incident Diabetes Mellitus in Older Non-Diabetic Adults Randomized to Three Different Classes of Antihypertensive.

Heart Failure (HF) Findings: Are They Real? Stanley S. Franklin, MD, FACP, FACC Clinical Professor of Medicine University of California at Irvine Associate.

HvC Comparative Effectiveness Project Groups 5 and 6

Heart failure: The national burden AHA. Heart disease and stroke statistics–2005 update. Koelling TM et al. Am Heart J. 2004;147:74-8. VBWG Affects 1 million.

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:

7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.

Thiazide diuretics, Potassium, and the Development of Diabetes A Quantitative Review Hypertension2006_219.

Innovations in Management of Cardiovascular Disease for Global Health

HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING

New Guidelines for Myocardial Ischemia Management.

Efficacy and Comparability of Thiazide-type Diuretics

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

Pre-ALLHAT Drug Use IMS Health NDTI, Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors.

ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.

JNC 7 血壓分期. 血壓分期 JNC 7 ： 1. 增加高血壓前期 2.Stages 2 及 3 高血壓被合併 JNC 7, 2003.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Characteristics of studies on lifestyle interventions included in review Gillies CL, et al. BMJ 2007;334:

Update in Cardiology A Cardiologist’s Eye for the Primary Guy Abdul H Sankari Heartland Cardiovascular Center.

Blood Pressure and Lipid Trials: Rationale, Importance and Design

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

Health and Human Services National Heart, Lung, and Blood Institute

Copyright © 2000 American Medical Association. All rights reserved.

ALLHAT ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status.

Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

Emerging Mechanisms in Glucose Metabolism

ALLHAT: What Outcomes Would Have Been Expected?

Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors

Losartan vs. Atenolol in Marfan Syndrome

Relative risk of major events with atenolol vs placebo

Outcome Relative risk with beta blockers 95% CI Stroke –1.30

Health and Human Services National Heart, Lung, and Blood Institute

2014 Update on Hypertension

β-Blockers in Heart Failure: Breaking Tradition to Avoid Diabetes?

Table of Contents Why Do We Treat Hypertension? Recommendation 5

Post-Heart Failure Mortality

The following slides highlight a report by Dr

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Expected value of perfect implementation: population net health benefit and maximum justifiable investment if all patients who were eligible received beta.

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. Meta-analysis of trials examining the effects.

PHOENIX I: PASI 75 Response After 12 Weeks

© The Author(s) Published by Science and Education Publishing.

Presentation transcript:

Why wasn’t a beta-blocker tested as first-line therapy? ALLHAT Why wasn’t a beta-blocker tested as first-line therapy?

Reasons for no beta-blocker arm Feasibility considerations allowed only 3-4 arms--traditional drug(s), ACEI, CCB, +1? Traditional drug choices considered—diuretic, beta-blocker, or either/both. Most hypertension trials used diuretics. Pooled results of 3 older diuretic vs. beta-blocker trials showed no CVD differences. (Collins et al. Lancet 1990;335:827-38)

Reasons for no beta-blocker arm (continued) Concerns about beta-blockers in patients with diabetes (oversampled in ALLHAT), although UKPDS results (atenolol vs captopril) subsequently lessened concerns (BMJ 1998;317:713-720). Pooled analyses of 18 trials →low-dose diuretics but not beta-blockers prevent first CHD events (Psaty et al. JAMA 1997;277:739-45).